Form 4: Anne McGeorge, Dianthus Therapeutics Director, Acquires 11,000 Stock Options
SEC Form 4 Filing
Director Anne McGeorge acquired 11,000 stock options in Dianthus Therapeutics on May 23, 2024, according to a Form 4 filing.
Summary
- Anne McGeorge, a director of Dianthus Therapeutics, acquired 11,000 stock options on May 23, 2024.
- The exercise price of these options is $21.77.
- The options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service.
- The options expire on May 22, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option acquisition by a company director, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: Anne McGeorge acquired 11,000 stock options. |
| 05/22/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.